Status: Not yet recruiting
A Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Inhaled H057 in the Treatment of Acute Exacerbations of Bronchiectasis
This is a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of inhaled H057 in the treatment of acute exacerbations of bronchiectasis.
Participants needed: 180
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Shanghai Huilun Pharmaceutical Co., Ltd.Updated: May 9, 2025Locations: 19
Eligibility criteria
Age ≥18 years, regardless of gender; [+4]
Patients with bronchiectasis caused by cystic fibrosis, as determined by the inv... [+13]